News | Heart Failure | September 05, 2017

Israeli Hospital Completes First Implant of CORolla Heart Failure Device

First implant of elastic device implanted in the left ventricle is completed on 72-year-old patient

Israeli Hospital Completes First Implant of CORolla Heart Failure Device

September 5, 2017 — Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company CorAssist in a 72-year-old diastolic heart failure patient.

There are several types of heart failure based on the mode of heart dysfunction. Diastolic heart failure occurs when the left ventricle fails to relax and adequately refill with blood, resulting in a high filling pressure, congestion and shortness of breath. Approximately half of heart failure patients suffer from diastolic heart failure. The incidence of diastolic heart failure increases with age and is common among women with hypertension, obesity and diabetes. There is currently no effective proven treatment for this condition.

CorAssist developed the CORolla, an elastic device that is implanted inside the left ventricle of the heart by a minimally invasive procedure on a beating heart. The device can improve cardiac diastolic function by applying direct expansion force on the ventricle wall to help the heart fill with blood. The CorAssist technology was invented by Yair Feld, M.D., Ph.D., a cardiologist at Rambam Health Care Campus, together with partners Yotam Reisner, M.D., Ph.D., and Shay Dubi, M.D., Ph.D.

Prof. Gil Bolotin, director of the Department of Cardiac Surgery, and Dr. Arthur Kerner, senior physician in the Interventional Cardiology Unit, recently led a multi-disciplinary team of cardiologists, heart surgeons and other Rambam medical professionals in the first clinical implantation surgery on the 72-year old Canadian man admitted specifically for this procedure.

When asked how and why he came to Rambam for the procedure, Robert MacLachlan explained that he had run out of treatment options in Canada for his diastolic heart failure. His wife had read about the CORolla implant on the Internet and contacted Dr. Karen Bitton Worms, head of research – Department of Cardiac Surgery at Rambam.  MacLachlan's cardiologist encouraged him to apply. Bolotin explained that while many potential applicants were interested in the procedure, no one wanted to be first.

The Israel Ministry of Health has authorized up to 10 clinical trials at Rambam in Israel to test the efficacy of cardiac catheterization for placement of the CORolla implant.

Watch a video animation demonstrating how the CORolla device works.

Read the related article “Device Technologies to Reduce Heart Failure Readmissions.”

Watch the VIDEO “Technologies to Reduce Heart Failure Readmissions.”

For more information: www.corassist.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...